SCHEMBL23167682

SCHEMBL23167682

CCCc1cc(O)c(C2C=C(C)CCC2)c(O)c1C(=O)NC

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 13/20 0.57
DAGLA Q9Y4D2 4/20 0.50
CNR2 P34972 9/20 0.43
NAAA Q02083 2/20 0.43
TRPV1 Q8NER1 2/20 0.37
TRPM8 Q7Z2W7 2/20 0.36
LDHA P00338 1/20 0.36
PPARG P37231 1/20 0.36
OPRM1 P35372 2/20 0.35
TRPA1 O75762 1/20 0.35
CYP1A1 P04798 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2B6 P20813 1/20 0.35
SLC6A2 P23975 1/20 0.35
CYP2C19 P33261 1/20 0.35
GPR6 P46095 1/20 0.35
SLC6A3 Q01959 1/20 0.35
TRPV3 Q8NET8 1/20 0.35
TRPV4 Q9HBA0 1/20 0.35
GPR55 Q9Y2T6 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29911973 1.00 CNR1 (0.57) CNR1DAGLACNR2NAAATRPV1
SCHEMBL29730411 0.93 CNR1 (0.67) CNR1DAGLACNR2NAAATRPV1
SCHEMBL23168056 0.93 CNR1 (0.67) CNR1DAGLACNR2NAAATRPV1
SCHEMBL23158569 0.88 DAGLA (0.64) CNR1DAGLACNR2NAAATRPV1
SCHEMBL23765189 0.88 DAGLA (0.64) CNR1DAGLACNR2NAAATRPV1
SCHEMBL23155074 0.87 CNR1 (0.57) CNR1DAGLACNR2NAAATRPV1
SCHEMBL23167667 0.85 CNR1 (0.56) CNR1DAGLACNR2NAAATRPV1
SCHEMBL23207688 0.85 CNR1 (0.47) CNR1DAGLACNR2NAAATRPM8
SCHEMBL23167683 0.83 CNR1 (0.58) CNR1DAGLACNR2NAAATRPV1
SCHEMBL23167748 0.83 CNR1 (0.68) CNR1DAGLACNR2NAAATRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12325709-B2 Cannabinoid derivatives CANOPY GROWTH CORPORATION (CA) 2025-06-10 US claimed
US-20220348586-A1 CANNABINOID DERIVATIVES JGB COLLATERAL LLC 2022-11-03 US claimed
EP-4037676-A1 CANNABINOID DERIVATIVES Canopy Growth Corporation (CA) 2022-08-10 EP claimed
WO-2021062559-A1 CANNABINOID DERIVATIVES CANOPY GROWTH CORPORATION (CA) 2021-04-08 WO claimed
US-12325709-B2 Cannabinoid derivatives CANOPY GROWTH CORPORATION (CA) 2025-06-10 US disclosed
US-20220348586-A1 CANNABINOID DERIVATIVES JGB COLLATERAL LLC 2022-11-03 US disclosed
EP-4037676-A1 CANNABINOID DERIVATIVES Canopy Growth Corporation (CA) 2022-08-10 EP disclosed
WO-2021062559-A1 CANNABINOID DERIVATIVES CANOPY GROWTH CORPORATION (CA) 2021-04-08 WO disclosed
WO-2021062559-A1 CANNABINOID DERIVATIVES CANOPY GROWTH CORPORATION (CA) 2021-04-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12325709-B2 Cannabinoid derivatives CNR1, CNR2, GPR68 CNR1 1/4885DAGLA 596/4885CNR2 2/4885
US-20220348586-A1 CANNABINOID DERIVATIVES CNR1, CNR2, GPR68 CNR1 1/4885DAGLA 596/4885CNR2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.